Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Stem Cell (CSC) and Solid Tumor Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CRIPTO/TDGF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CRIPTO/TDGF1 ECD-Fc / His Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CRIPTO Products |
| Gene Delivery | CRIPTO/TDGF1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based assays. |
View CRIPTO Products |
| Benchmark Ab | Anti-CRIPTO/TDGF1 Recombinant Antibody Sequence-derived positive control for binding and internalization assays. |
View CRIPTO Products |
| Validator | CRIPTO/TDGF1 siRNA Set For target knockdown and specificity validation in cell-based assays. |
View CRIPTO Products |
| Related Target A | NODAL Core ligand that heterodimerizes with CRIPTO to trigger Smad2/3 signaling. |
View NODAL Products |
| Related Target B | ALK4 (ACVR1B) Type I receptor partner recruited by CRIPTO to initiate downstream signaling. |
View ALK4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Soluble Receptor Shedding Interference | High-purity recombinant proteins with verified theoretical molecular weight, enabling precise decoy-receptor affinity profiling. |
| Glycosylation-Dependent Binding (O-Fucosylation) | HEK293 mammalian expression host ensures native post-translational modifications and correct folding of the EGF-like domain. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CRIPTO/TDGF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CRIPTO/TDGF1 therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies (mAbs) to Antibody-Drug Conjugates (ADCs) and bispecific constructs. As first-generation therapies targeting embryonal and cancer stem cell pathways reach the clinic, the next wave of R&D is targeting the suppression of EMT (Epithelial-Mesenchymal Transition) and drug-resistant oncogenic niches.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Biotech & Pharma Consortia | Breast, Colon, and Lung Cancers | Internalization Assay (Requires high-purity, natively glycosylated ECD-Fc) |
| Bispecific / Multispecific Ab | Immuno-oncology Innovators | Refractory Solid Tumors | Dual-affinity validation (Requires high-purity CRIPTO and ALK4/NODAL proteins) |
| Cell Therapy (CAR-T / CAR-NK) | Academic Research Centers | Glioblastoma, Pancreatic Cancer | Cell line construction with native conformation (Requires Lentivirus for stable expression) |